(Q34666666)

3 August 2017

1 reference

title

Antifungal drug resistance: does it matter? (English)

1 reference

antifungal drug resistance

3 August 2017

main subject

1 reference

Thomas R Rogers

1

1 reference

3 August 2017

publication date

1 March 2002

1 reference

International Journal of Infectious Diseases

3 August 2017

published in

1 reference

3 August 2017

volume

6 Suppl 1

1 reference

3 August 2017

page(s)

S47-53

1 reference

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Flucytosine monotherapy for cryptococcosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Resistance of Candida species to fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Mechanism of fluconazole resistance in Candida krusei

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Characterization of an azole-resistant Candida glabrata isolate

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Cross-resistance to polyene and azole drugs in Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

The combination of oral amphotericin B with azoles prevents the emergence of resistant Candida species in neutropenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Interferon gamma and granulocyte-macrophage colony-stimulating factor for the treatment of hepatosplenic candidosis in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Role of dimorphism in the development of Candida albicans biofilms.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Antifungal resistance and over-the-counter availability in the UK: a current perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Antifungal susceptibility testing: practical aspects and current challenges

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Amphotericin B-resistant yeast infection in severely immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

Itraconazole resistance in Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2802%2990154-2

7 January 2021

10.1016/S1201-9712(02)90154-2

Identifiers

DOI

1 reference

3 August 2017

1 reference